Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Luster

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawalR Elisei, M Schlumberger, A Driedger, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyF Pacini, P W Ladenson, M Schlumberger, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|June 8, 2018
[Update of the S2k guidelines : Surgical treatment of benign thyroid diseases]T J Musholt, A Bockisch, T Clerici, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancerB R Haugen, F Pacini, C Reiners, et al.
Langenbeck'S Archives of Surgery|April 21, 2021
Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK)T Weber, C Dotzenrath, H Dralle, et al.
Endocrine Connections|November 6, 2023
Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocolS C Clement, W E Visser, C A Lebbink, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
The Journal of Clinical Endocrinology and Metabolism|October 24, 2009
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawalR Elisei, M Schlumberger, A Driedger, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2005
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled studyF Pacini, P W Ladenson, M Schlumberger, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|June 8, 2018
[Update of the S2k guidelines : Surgical treatment of benign thyroid diseases]T J Musholt, A Bockisch, T Clerici, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancerB R Haugen, F Pacini, C Reiners, et al.
Langenbeck'S Archives of Surgery|April 21, 2021
Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK)T Weber, C Dotzenrath, H Dralle, et al.
Endocrine Connections|November 6, 2023
Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocolS C Clement, W E Visser, C A Lebbink, et al.
Pageof 7